Log in

Relevant bibliographies by topics / Myers, Kevin / Journal articles

To see the other types of publications on this topic, follow the link: Myers, Kevin.

Journal articles on the topic 'Myers, Kevin'

Author: Grafiati

Published: 25 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Myers, Kevin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Myers, Edward A., Luigie Alequín, Ayanna Browne, et al. "Population divergence in co-distributed Caribbean landfrogs (Eleutherodactylidae: Eleutherodactylus) along the Soufrière volcanic slope of Guadeloupe Island, Lesser Antilles." Zoological Journal of the Linnean Society 202, no. 4 (2024): 1–13. https://doi.org/10.1093/zoolinnean/zlae128.

Full text

Abstract:

Myers, Edward A, Alequín, Luigie, Browne, Ayanna, Mulder, Kevin P, Rivera, Danielle, Esposito, Lauren A, Bell, Rayna C, Hedges, S Blair (2024): Population divergence in co-distributed Caribbean landfrogs (Eleutherodactylidae: Eleutherodactylus) along the Soufrière volcanic slope of Guadeloupe Island, Lesser Antilles. Zoological Journal of the Linnean Society (zlae128) 202 (4): 1-13, DOI: 10.1093/zoolinnean/zlae128, URL: https://doi.org/10.1093/zoolinnean/zlae128

APA, Harvard, Vancouver, ISO, and other styles

2

Macpherson, Jim. "Struggles for a Past: Irish and Afro-Caribbean Histories in England, 1951–2000. By Kevin Myers." Twentieth Century British History 30, no. 4 (2018): 618–20. http://dx.doi.org/10.1093/tcbh/hwy030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gerrard, Jessica. "Struggles for a past: Irish and Afro-Caribbean histories in England, 1951–2000, by Kevin Myers." History of Education 46, no. 4 (2016): 533–34. http://dx.doi.org/10.1080/0046760x.2016.1181798.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Arriens, C., A. Askanase, R. Furie, et al. "AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1463.1–1463. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3881.

Full text

Abstract:

BackgroundDeucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis[1,2]. Deucravacitinib demonstrated efficacy across the primary endpoint and all key secondary endpoints in a phase 2 trial in patients with systemic lupus erythematosus (SLE)[3].ObjectivesHere, we describe 2 phase 3 trials currently underway to assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the p

APA, Harvard, Vancouver, ISO, and other styles

5

Choy, E., S. Henning, M. Brazil, et al. "AB0347 TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1299.1–1299. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2356.

Full text

Abstract:

BackgroundA previous real-world study has reported the characteristics, treatment patterns and clinical outcomes of patients with rheumatoid arthritis (RA) who received abatacept in UK clinical practice.1,2 However, many of the eligible population received abatacept monotherapy rather than as indicated. A subgroup analysis of patients treated with abatacept in combination with methotrexate (ABA + MTX) was therefore undertaken to explore the treatment effect in this specific patient population.ObjectivesPresent a subgroup analysis describing the clinical outcomes of patients with RA treated wit

APA, Harvard, Vancouver, ISO, and other styles

6

Curtis, J., K. Winthrop, B. Chan, et al. "FRI0314 ANNUAL DIAGNOSTIC PREVALENCE OF ANKYLOSING SPONDYLITIS (AS) IN THE UNITED STATES USING MEDICARE AND MARKETSCAN DATA." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 747.1–748. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4246.

Full text

Abstract:

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that affects the axial skeleton and sacroiliac joints, and can be classified as ankylosing spondylitis (AS) or non-radiographic (nr)-axSpA.1A 2016 analysis estimated the US diagnostic prevalence of axSpA to be 0.2% and AS to be 0.1%.2Previous studies use disparate populations and diagnostic definitions;3,4it is therefore unclear how AS prevalence has changed over time.Objectives:To investigate the annual diagnostic prevalence of AS in US healthcare insurance claims databases.Methods:A retrospective, observational coho

APA, Harvard, Vancouver, ISO, and other styles

7

Korman, N. J., T. Passeron, K. B. Gordon, et al. "AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1774–75. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1533.

Full text

Abstract:

BackgroundTyrosine kinase 2 (TYK2) is an intracellular enzyme involved in IL-23 signaling that is important in the pathogenesis of immune-mediated diseases, including psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE). Deucravacitinib is a first-in-class, oral, selective, allosteric TYK2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib uniquely binds to the TYK2 regulatory domain rather than the more conserved catalytic domain at which Janus kinase (JAK) 1/2/3 inhibitors bind. Deucravacitinib was efficacious compare

APA, Harvard, Vancouver, ISO, and other styles

8

Deodhar, A., K. Winthrop, R. Bohn, et al. "SAT0370 TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1132.1–1133. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4201.

Full text

Abstract:

Background:Comorbidities and extra-articular manifestations (EAMs) substantially increase disease burden and mortality risk in patients (pts) with ankylosing spondylitis (AS).1,2Tumour necrosis factor inhibitors (TNFi) are highly efficacious and effective in AS treatment (tx), and are used after inadequate response to non-steroidal anti-inflammatory drugs.3,4However, the impact of TNFi on the incidence of comorbidities and EAMs in pts with AS is unknown.5Objectives:To determine the incidence of comorbidities and EAMs in TNFi vs non-TNFi treated pts with AS in the US.Methods:This was a retrospe

APA, Harvard, Vancouver, ISO, and other styles

9

Winthrop, K., P. Nash, K. Yamaoka, et al. "THU0218 INCIDENCE AND RISK FACTORS FOR HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING UPADACITINIB." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 335–36. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2744.

Full text

Abstract:

Background:Upadacitinib (UPA) is an oral JAK inhibitor approved for the treatment of rheumatoid arthritis (RA). The background rate of herpes zoster (HZ) in patients (pts) with RA is around 0.98/100 person years (PY)1. Pts with RA receiving JAK inhibitors have been reported to have an increased risk of HZ.Objectives:To evaluate the incidence and risk factors for HZ in pts with RA receiving UPA relative to active comparators in the Phase 3 clinical trial program.Methods:The incidence rate of HZ was determined in pts receiving UPA (as monotherapy [mono] or combination therapy) in five randomized

APA, Harvard, Vancouver, ISO, and other styles

10

Aletaha, D., P. J. Mease, R. Lippe, et al. "POS1026 PREDICTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT WEEK 56 IN PATIENTS WITH PSORIATIC ARTHRITIS WHO RECEIVED UPADACITINIB 15 MG ONCE DAILY: POOLED ANALYSIS OF TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 824.2–825. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1291.

Full text

Abstract:

BackgroundUpadacitinib (UPA) 15 mg once daily (QD) has demonstrated efficacy and safety in patients with psoriatic arthritis (PsA) for up to 56 weeks in the Phase 3 SELECT-PsA 1 and 2 trials.1,2ObjectivesThis post hoc analysis of these studies explored the association of baseline characteristics and short-term responses with achievement of minimal disease activity (MDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) low disease activity (LDA).MethodsData were pooled from patients with prior inadequate response or intolerance to ≥1 non-biologic (b) DMARDs (SELECT-PsA 1) or ≥1 bDMARD

APA, Harvard, Vancouver, ISO, and other styles

11

Baraliakos, X., R. Ranza, A. Ostor, et al. "POS0934 EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PRO-BASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 768. http://dx.doi.org/10.1136/annrheumdis-2022-eular.722.

Full text

Abstract:

BackgroundPatients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for identifying axial involvement in PsA.ObjectivesThe objective of this post-hoc analysis is to assess the efficacy of upadacitinib (UPA), a Janus kinase inhibitor, on axial symptoms in patients with active PsA and axial involvement defined by investigator assessment and PRO-based criteria from two phase 3 SELECT trials.2,3MethodsPatients with active PsA (≥3 swollen joints and ≥3 tender joints) and prior inadequate response or intol

APA, Harvard, Vancouver, ISO, and other styles

12

Roth, Andreas. "Francis Stuart’s broadcasts from Germany, 1942—4: some new evidence." Irish Historical Studies 32, no. 127 (2001): 408–22. http://dx.doi.org/10.1017/s002112140001508x.

Full text

Abstract:

The poet and novelist Francis Stuart’s sojourn in Germany during the Second World War and his broadcasting activities for the Nazis remain acnámh spairneamong historians and journalists alike. Assessments of his radio talks range from that of his biographer J.H. Natterstad, who described them as being of ‘a literary or semi-literary’ character, to that of Kevin Myers, who equated the broadcasts with ‘voluntary siding with the most bestial régime in the history of civilisation’. In October 1997 a television documentary during which Stuart was quoted as saying that ‘the Jew was always the worm t

APA, Harvard, Vancouver, ISO, and other styles

13

Gottlieb, A. B., F. Behrens, P. Nash, et al. "FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 763.2–764. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4736.

Full text

Abstract:

Background:Psoriatic arthritis (PsA) is a heterogeneous disease comprising musculoskeletal and dermatological manifestations, especially plaque psoriasis.1Secukinumab (SEC), an IL-17A inhibitor, provided significantly greater PASI 75/100 responses in a head-to-head trialversus (vs.) etanercept, a TNF inhibitor, in patients (pts) with moderate-to-severe plaque psoriasis.2The objective of the EXCEED study (NCT02745080) was to investigate whether SEC is superior to adalimumab (ADA), a TNF inhibitor, as monotherapy in biologic-naive active PsA pts with active plaque psoriasis (defined as having at

APA, Harvard, Vancouver, ISO, and other styles

14

Lininger, N., S. Siegel, S. Kiwalkar, K. Winthrop, A. Ortega Loayza, and A. Deodhar. "FRI0555 DO TNF INHIBITORS DECREASE RISK OF INCIDENT PSORIATIC ARTHRITIS IN PSORIASIS PATIENTS COMPARED TO THOSE TREATED WITH METHOTREXATE ALONE?" Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 879.2–880. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4983.

Full text

Abstract:

Background:Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterized by joint and entheseal inflammation seen in 30% patients with psoriasis (Pso). In 90% of patients, Pso precedes PsA. Inhibitors of tumor necrosis factor (TNFi) are efficacious treatment options for both, though whether they prevent development of incident PsA in Pso patients is unknown.Objectives:To determine if the use of TNFi reduces the risk of developing psoriatic arthritis in Pso patients compared to those treated with methotrexate alone.Methods:Records on all Pso patients seen at dermatology clinic at

APA, Harvard, Vancouver, ISO, and other styles

15

Turnage, Richard H., John L. Lanoue, Kevin M. Kadesky, Yan Meng, and Stuart I. Myers. "Thromboxane A2 mediates increased pulmonary microvascular permeability after intestinal reperfusion." Journal of Applied Physiology 82, no. 2 (1997): 592–98. http://dx.doi.org/10.1152/jappl.1997.82.2.592.

Full text

Abstract:

Turnage, Richard H., John L. LaNoue, Kevin M. Kadesky, Yan Meng, and Stuart I. Myers. Thromboxane A2 mediates increased pulmonary microvascular permeability after intestinal reperfusion. J. Appl. Physiol. 82(2): 592–598, 1997.—This study examines the hypothesis that intestinal reperfusion (IR)-induced pulmonary thromboxane A2(TxA2) release increases local microvascular permeability and induces pulmonary vasoconstriction. Sprague-Dawley rats underwent 120 min of intestinal ischemia and 60 min of IR. Sham-operated animals (Sham) served as controls. After IR or Sham, the pulmonary vessels were ca

APA, Harvard, Vancouver, ISO, and other styles

16

Stefanovska, Bojana, Kevin Lin, Benjamin Troness, Chad Myers, and Reuben Harris. "Abstract P2-17-01: Targeted CRISPR screen to identify synthetic lethal combinations between APOBEC3B and DNA repair." Cancer Research 83, no. 5_Supplement (2023): P2–17–01—P2–17–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-17-01.

Full text

Abstract:

Abstract APOBEC-catalyzed deamination of cytosine bases is the largest enzymatic and second largest overall source of mutation in cancer. One member from the APOBEC family of enzymes, APOBEC3B (A3B) is overexpressed and dysregulated in many different cancer types. In addition to hallmark C-to-T transitions and C-to-G transversions, APOBEC-catalyzed uracil lesions can be processed into single- and double-strand DNA breaks. Therefore, A3B-positive tumors are under continual stress to repair DNA breaks and may be vulnerable to DNA repair inhibition. Previous results from the Harris lab have ident

APA, Harvard, Vancouver, ISO, and other styles

17

Mcinnes, I., F. Behrens, P. J. Mease, et al. "OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 142–43. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4129.

Full text

Abstract:

Background:Secukinumab (SEC), an interleukin-17A inhibitor, has demonstrated improvements on multiple domains of psoriatic arthritis (PsA).1Adalimumab (ADA), a TNF inhibitor, is widely used as a first–line biologic in PsA.Objectives:To report efficacy and safety outcomes from the head-to-head EXCEED trial (NCT02745080) that compares SECvs.ADA as first–line biologic monotherapy through 52-weeks (wks), with a musculoskeletal primary endpoint in pts with active PsA.Methods:Head-to-head, phase-3b, randomised, double-blind trial: biologic naïve active PsA pts were randomised to receive SEC 300mg su

APA, Harvard, Vancouver, ISO, and other styles

18

Genovese, M. C., K. Winthrop, Y. Tanaka, et al. "THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 324–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.267.

Full text

Abstract:

Background:Filgotinib (FIL), an oral, potent, selective JAK-1 inhibitor, provided statistically significant and clinically meaningful improvement in rheumatoid arthritis (RA) signs and symptoms, physical function, radiographic progression, and quality of life in a comprehensive clinical program of 4 phase 3 (FINCH 1–4;NCT02889796,NCT02873936,NCT02886728,NCT03025308) and 3 phase 2 (DARWIN 1–3;NCT01668641,NCT01894516,NCT02065700) trials in patients (pts) with early and biologic-refractory RA.1–3Objectives:To assess long-term safety of FIL.Methods:Treatment-emergent adverse events (TEAEs) from th

APA, Harvard, Vancouver, ISO, and other styles

19

Bykerk, V., A. B. Gottlieb, K. Reich, et al. "FRI0087 DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 621.1–621. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1682.

Full text

Abstract:

Background:Durability over time varies according to the safety, tolerability and efficacy of a drug.1However, durability may vary between patient (pt) subgroups,1,2and physicians should consider pt characteristics when making treatment decisions. Certolizumab pegol (CZP) is an anti-tumour necrosis factor (anti-TNF) agent approved for the treatment of chronic inflammatory diseases, including rheumatoid arthritis (RA) and plaque psoriasis (PSO).3However, little is known about the impact of pt baseline characteristics on long-term CZP durability.Objectives:To investigate the durability of CZP and

APA, Harvard, Vancouver, ISO, and other styles

20

KITLV, Redactie. "Book Reviews." New West Indian Guide / Nieuwe West-Indische Gids 62, no. 3-4 (1988): 165–209. http://dx.doi.org/10.1163/13822373-90002043.

Full text

Abstract:

-William Roseberry, Michel-Rolph Trouillot, Peasants and capital: Dominica in the world economy. Baltimore and London: The Johns Hopkins University Press. Johns Hopkins Studies in Atlantic History and Culture, 1988. xiv + 344 pp.-Michel-Rolph Trouillot, Robert A. Myers, Dominica. Oxford, Santa Barbara, Denver: Clio Press, World Bibliographic Series, volume 82. xxv + 190 pp.-Michel-Rolph Trouillot, Robert A. Myers, A resource guide to Dominica, 1493-1986. New Haven: Human Area Files, HRA Flex Books, Bibliography Series, 1987. 3 volumes. xxxv + 649.-Stephen D. Glazier, Colin G. Clarke, East Indi

APA, Harvard, Vancouver, ISO, and other styles

21

Mease, P. J., A. Kavanaugh, D. D. Gladman, et al. "AB0529 CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1294–95. http://dx.doi.org/10.1136/annrheumdis-2021-eular.574.

Full text

Abstract:

Background:For patients (pts) with PsA, several disease activity measures are available including very low/minimal disease activity (VLDA/MDA), cutoffs based on the Disease Activity in PsA (DAPSA) score, and on the Psoriatic Arthritis Disease Activity Score (PASDAS) score.Objectives:To assess the rates of pts achieving these remission or low disease activity (LDA) criteria at Wk 24 using data from the SELECT-PsA 1 and SELECT-PsA 2 phase 3 studies;1,2 Additionally, we assessed the distribution of individual MDA components among pts who did or did not achieve MDA criteria at Wk 24.Methods:In SEL

APA, Harvard, Vancouver, ISO, and other styles

22

Hirano, A., W. Fujii, A. Sakashita, et al. "POS0151 SINGLE-CELL RNA SEQUENCING OF BRONCHOALVEOLAR LAVAGE FLUID AND BLOOD REVEALS DISEASE-SPECIFIC CHARACTERISTICS OF IMMUNE CELLS IN CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE PATIENTS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 296–97. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2875.

Full text

Abstract:

BackgroundConnective tissue disease-associated interstitial lung disease (CTD-ILD) is a serious complication and an important prognostic factor of various autoimmune diseases. Many cell types and both innate and adaptive immune systems are implicated in the pathogenesis of fibrotic lung injury. The presentation and clinical course of CTD-ILD are diverse, and the heterogeneity reflects differences in underlying pathogenic mechanisms.ObjectivesThe objective of this study is to reveal the different characteristics of immune cells among diseases.MethodsWe collected bronchoalveolar lavage fluid (BA

APA, Harvard, Vancouver, ISO, and other styles

23

Kavanaugh, A., P. J. Mease, K. Douglas, et al. "AB0547 ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIES." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1306.2–1307. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2000.

Full text

Abstract:

Background:The efficacy and safety of upadacitinib (UPA) in patients (pts) with active psoriatic arthritis (PsA) was demonstrated in the phase 3 SELECT-PsA 1 and SELECT-PsA 2 clinical trials.1,2Objectives:To explore the relationship between achievement of low disease activity (LDA) or remission (REM) and pt-reported outcomes (PROs) in SELECT-PsA 1 and 2.Methods:The SELECT-PsA program enrolled pts with prior inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug (DMARD; SELECT-PsA 1) or ≥1 biologic DMARD (SELECT-PsA 2). Pts were randomized to 56 weeks (wks) o

APA, Harvard, Vancouver, ISO, and other styles

24

Merola, J. F., I. Mcinnes, A. Kavanaugh, et al. "POS1029 EFFECTS OF TREATMENT WITH RISANKIZUMAB ON MINIMAL DISEASE ACTIVITY (MDA) AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (DAPSA): AN ANALYSIS OF THE KEEPsAKE-1 AND -2 TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 827. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1362.

Full text

Abstract:

BackgroundRisankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23.ObjectivesTo evaluate the achievement of Minimal Disease Activity (MDA), its components, and achievement of Disease Activity in PsA Low Disease Activity and Remission (DAPSA LDA+REM, [DAPSA score ≤14]) in patients receiving RZB or placebo (PBO) in the KEEPsAKE 1 and 2 clinical trials.MethodsKEEPsAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus PBO for the treatment of adult patients with active psoriatic arthritis (PsA). Patients were randomized (1:1) to receive subcu

APA, Harvard, Vancouver, ISO, and other styles

25

Merrill, J. T., M. Smith, K. Thomas, et al. "POS1154 PRE-TREATMENT DIFFERENTIALLY EXPRESSED METAGENES CHARACTERIZE SYSTEMIC LUPUS PATIENTS WHO SUBSEQUENTLY ACHIEVE CLINICAL RESPONSE TO BELIMUMAB." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 908–9. http://dx.doi.org/10.1136/annrheumdis-2023-eular.4022.

Full text

Abstract:

BackgroundBelimumab, which targets the B Cell activator and survival factor BLyS, is an approved treatment for systemic lupus (SLE) and has demonstrated efficacy in multiple clinical trials around the world. Nevertheless, like other SLE treatments, belimumab can have disappointing results in a significant proportion of this heterogenous population, a problem further complicated by the unpredictable impact of various combination treatments used with belimumab in trials and clinical practice.ObjectivesExamination of gene expression variables in SLE patients prior to belimumab treatment with limi

APA, Harvard, Vancouver, ISO, and other styles

26

Fujii, W., A. Sakashita, A. Hirano, et al. "POS0616 THE CHARACTERISTICS OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE IN CONNECTIVE TISSUE DISEASES WITH SINGLE-CELL RNA SEQUENCING OF BRONCHOALVEOLAR LAVAGE FLUID." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 580.1–581. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2140.

Full text

Abstract:

BackgroundConnective tissue disease-associated interstitial lung disease (CTD-ILD) is a severe complication of rheumatic and musculoskeletal diseases, e.g. rheumatoid arthritis (RA), dermatomyositis (DM), systemic sclerosis (SSc) and so on. CTD-ILD is a heterogeneous syndrome driven by different diseases and cell types. This complexity provides a challenging field for elucidating the mechanism of the disease. Although some patients with CTD-ILD develop progressive fibrosing interstitial lung disease (PF-ILD) like as other ILD despite immunosuppressive treatment, it is difficult to predict whic

APA, Harvard, Vancouver, ISO, and other styles

27

Canabal Berlanga, Alfonso. "Polarización social, mecanismos emotivos y racionales de pensamiento grupal." Relectiones. Revista interdisciplinar de filosofía y humanidades., no. 12 (May 28, 2025): 119–33. https://doi.org/10.32466/eufv-rel.2025.12.842.119-133.

Full text

Abstract:

Objetivo: Analizar la polarización social desde el punto de vista de la psicología social y filosofía, describir mecanismo racionales e irracionales de su generación, relacionarlo con la sociedad postmoderna Metodología: se trata de un análisis argumentativo sobre la polarización social. Utilizaremos bibliografía con diferentes orientaciones y puntos de vista, analizando mecanismos de generación de la polarización y repercusiones. Resultados: La polarización grupal es un fenómeno de pensamiento que se ha podido reflejar en la sociedad en diferentes momentos de la historia y que en el momento a

APA, Harvard, Vancouver, ISO, and other styles

28

Galloway, J., M. H. Buch, K. Yamaoka, et al. "OP0126 INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 70–71. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1416.

Full text

Abstract:

Background:The Janus kinase (JAK)-1 preferential inhibitor filgotinib (FIL) improved rheumatoid arthritis (RA) signs and symptoms in 3 phase (P)3 trials.1–3 Like other RA therapies, JAK inhibition is associated with increased infection rates.4Objectives:To assess long-term safety across the FIL program regarding infections, including serious infections (SI).Methods:Patients (pts) meeting 2010 ACR/EULAR RA criteria in pooled analysis of P2 DARWIN 1–2 (D1–2), P3 FINCH 1–3 (F1–3), and long-term extension studies (DARWIN 3, FINCH 4) were included. The placebo (PBO)-controlled as-randomised data se

APA, Harvard, Vancouver, ISO, and other styles

29

Costello, R. E., J. Humphreys, K. Winthrop, and W. Dixon. "SAT0065 TIMING OF PNEUMOCOCCAL VACCINATIONS IN RELATION TO STARTING DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 965.1–966. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1157.

Full text

Abstract:

Background:Pneumococcal vaccinations are recommended for patients with rheumatoid arthritis (RA). There is evidence that pneumococcal vaccinations are less effective when administered after starting conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Vaccination guidelines have changed over time, since 1992 UK guidelines recommend pneumococcal vaccination for the immunocompromised, and in 2003 was expanded to all individual’s age ≥65 years. Guidelines from British Society of Rheumatology (2011) and EULAR (2019) advise to vaccinate prior to starting csDMARDs where possible

APA, Harvard, Vancouver, ISO, and other styles

30

Genovese, M. C., J. S. Smolen, T. Takeuchi, et al. "FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 642.1–643. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1723.

Full text

Abstract:

Background:Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and 2, approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults.Objectives:Here we update the drug’s safety profile with data up to 8.4 years of treatment.Methods:Long-term safety of bari was assessed from 9 completed randomized trials (5 Ph3, 3 Ph2, 1 Ph 1b) and 1 ongoing long-term extension (LTE) study. Incidence rates (IR) per 100 patient-years (PY) were calculated for all patients with RA treated with ≥1 dose of bari through 1-Sep-2019 (All-Bari-RA analysis set). IRs

APA, Harvard, Vancouver, ISO, and other styles

31

Winter, Timothy, Timothy Myers, Leandro Colli, et al. "Abstract 6154: Targeted CRISPRi screen identifies functional variants and novel target genes at multiple renal cell carcinoma (RCC) susceptibility loci." Cancer Research 84, no. 6_Supplement (2024): 6154. http://dx.doi.org/10.1158/1538-7445.am2024-6154.

Full text

Abstract:

Abstract Genome-wide association studies (GWAS) have identified 13 renal cell carcinoma (RCC) risk regions, as well as 7 regions with nominal significance, but detailed investigation of how these regions function is required to reveal the underlying biological bases of disease susceptibility. While detailed study of four loci have implicated critical pathways in RCC, causal genes and pathways for most loci remain unidentified. To identify such causative variants and target genes, we evaluated a set of variants based on Massively Parallel Reporter Assays (MPRA), eQTL analysis, capture Hi-C, and

APA, Harvard, Vancouver, ISO, and other styles

32

Winthrop, K., D. Gold, D. Henrohn, et al. "SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1007–8. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1432.

Full text

Abstract:

Background:Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). A recent ad hoc safety analysis (as of August 2019; may be subject to change) from an ongoing, open-label, randomised, post-authorisation safety study, Study A3921133 (NCT02092467), conducted in RA patients (pts) aged ≥50 years with ≥1 cardiovascular risk factor has shown that incidence rates (IRs) of serious infection events (SIEs) were higher with tofacitinib 10 mg BID vs tumour necrosis factor inhibitors (TNFi; adalimumab [ADA] and etanercept) and this difference was more pronounced in p

APA, Harvard, Vancouver, ISO, and other styles

33

Hu, Fang Q., and Douglas M. Nark. "On a stabilization of the Ingard-Myers impedance boundary condition and its time domain implementation." International Journal of Aeroacoustics 23, no. 3-4 (2024): 318–41. http://dx.doi.org/10.1177/1475472x241230649.

Full text

Abstract:

It has been well-known that the Ingard-Myers impedance condition, while simple to apply, is subject to the hydrodynamic Kelvin-Helmholtz-type instability due to its use of a vortex sheet in modeling the flow at the liner boundary. Recently, in the development of a time domain boundary element method for acoustic scattering by treated surfaces, it was found that by neglecting a certain second-order spatial derivative term in the Ingard-Myers formulation, the hydrodynamic instability can be avoided. The present paper aims to provide further analysis of this modified condition, hereby referred to

APA, Harvard, Vancouver, ISO, and other styles

34

Thakur, Rohit, Mai Xu, Alexandra Thornock, et al. "Abstract 5239: Integrative analysis of 3D chromatin organization at GWAS loci identifies RAPGEF1 as a melanoma susceptibility gene." Cancer Research 83, no. 7_Supplement (2023): 5239. http://dx.doi.org/10.1158/1538-7445.am2023-5239.

Full text

Abstract:

Abstract Many GWAS loci occur in non-coding regions and often overlap with gene regulatory elements such as distant enhancers, making functional interpretation and target gene discovery challenging. The 3D chromatin organization brings enhancers in spatial proximity with a promoter to regulate target gene expression. Therefore, to map chromatin interactions between GWAS variants and target gene promoters we performed region-focused chromatin conformation capture assay (Capture-C) in primary human melanocytes. We baited the entire region of association for all 68 independent signals from the re

APA, Harvard, Vancouver, ISO, and other styles

35

Stefanovska, Bojana, Benjamin Troness, Kevin Lin, Chad Myers, and Reuben S. Harris. "Abstract P5-06-26: APOBEC3B And DNA Damage Repair As Synthetic Lethal Pairs." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–06–26—P5–06–26. https://doi.org/10.1158/1557-3265.sabcs24-p5-06-26.

Full text

Abstract:

Abstract APOBEC3 (A3) enzymes play a pivotal role in mutagenesis across various cancer types. These enzymes, which are single-stranded DNA cytosine deaminases, convert cytosine to uracil (C-to-U) as part of innate antiviral immune responses. Aberrant expression of A3 enzymes in several cancers leads to DNA damage, mutagenesis, and genomic instability. In breast cancer, in particular, APOBEC3B (A3B) is the major endogenous mutator that contributes to tumor evolution and resistance to treatment (1–4). DNA C-to-U deamination events result in characteristic C-to-T transitions and C-to-G transversi

APA, Harvard, Vancouver, ISO, and other styles

36

Kelnar, Kevin, Blaine Caughron, Holli Dale, et al. "Abstract P4-07-25: Verification of a Highly Sensitive, Circulating Cell-Free DNA and Exosomal RNA RT-qPCR Assay to Monitor ESR1 Mutations from a Liquid Biopsy." Clinical Cancer Research 31, no. 12_Supplement (2025): P4–07–25—P4–07–25. https://doi.org/10.1158/1557-3265.sabcs24-p4-07-25.

Full text

Abstract:

Abstract Introduction: At a rate of 90 new cases per 100,000 women per year, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) is the most prevalent subtype of breast cancer. Mutations in the ligand binding domain of the estrogen receptor gene (ESR1) are frequently the cause of resistance to aromatase inhibitor therapy. With repeat biopsy collection rarely performed after starting therapeutic treatment, early identification of ESR1 mutations in metastatic breast cancer (mBC) in plasma is critical after progression on aromatase inhibitor therapy and is in a

APA, Harvard, Vancouver, ISO, and other styles

37

Rims, C., V. Muir, K. Deane, et al. "THU0033 ALTERATIONS IN THE PHENOTYPIC LANDSCAPE AND SPECIFICITY OF CD4+ T CELLS IN CCP+ AT RISK SUBJECTS BEFORE THE ONSET OF RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 230.1–230. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1918.

Full text

Abstract:

Background:The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated protein antibody (ACPA) positivity in absence of arthritis at baseline, and is focused on defining how they transition from at-risk to classifiable disease. One potential mechanism is the expansion of antigen specific T cells that recognize self-antigens and acquisition of disease associated T cell phenotypes. ACPA emerge years prior to clinically apparent disease and subsequently increase in their

APA, Harvard, Vancouver, ISO, and other styles

38

Burmester, G. R., K. Winthrop, R. Blanco, et al. "AB0522 SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS FROM THE PHASE 3 PROGRAM." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1287–88. http://dx.doi.org/10.1136/annrheumdis-2021-eular.395.

Full text

Abstract:

Background:The efficacy and safety of upadacitinib (UPA), an oral Janus kinase inhibitor, in patients (pts) with active psoriatic arthritis (PsA) were demonstrated through 24 weeks in the phase 3 SELECT-PsA 1 and SELECT-PsA 2 placebo-controlled clinical trials.1,2Objectives:To describe the long-term integrated safety profile of UPA relative to adalimumab (ADA) in pts with PsA treated in the SELECT program.Methods:The SELECT-PsA program enrolled pts with prior inadequate response or intolerance to ≥1 non-biologic DMARD (SELECT-PsA 1) or ≥1 biologic DMARD (SELECT-PsA 2). Both trials include UPA

APA, Harvard, Vancouver, ISO, and other styles

39

Hu, Fang, and Douglas M. Nark. "A time domain boundary element method for acoustic scattering by lined surfaces in a subsonic uniform mean flow." Journal of the Acoustical Society of America 152, no. 4 (2022): A118. http://dx.doi.org/10.1121/10.0015737.

Full text

Abstract:

A time domain boundary integral equation with Burton-Miller reformulation is presented for acoustic scattering by surfaces with liners in a uniform mean flow. The Ingard-Myers impedance boundary condition is implemented using a broadband multipole impedance model which is in turn converted into time domain differential equations to augment the boundary integral equation. The coupled integral-differential equations are solved numerically by a March-On-in-Time (MOT) scheme. While the Ingard-Myers condition is known to support Kelvin-Helmholtz instability due to its use of a vortex sheet interfac

APA, Harvard, Vancouver, ISO, and other styles

40

Ai, R., D. Boyle, D. Hammaker, et al. "OP0337 DIFFERENTIAL METHYLATION OF PERIPHERAL BLOOD ADAPTIVE IMMUNE CELLS IN INDIVIDUALS AT HIGH RISK FOR RA AND WITH EARLY RA COMPARED WITH CONTROLS IDENTIFIES PATHWAYS IMPORTANT IN TRANSITION TO ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 207.2–207. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2989.

Full text

Abstract:

Background:The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing RA because of serum anti-citrullinated protein antibody positivity in absence of arthritis, and is focused on defining how they transition from at-risk to classifiable disease. One potential mechanism is through alterations in epigenetics patterns in adaptive immune cells.Objectives:Previous studies showed that DNA methylation patterns of early RA (ERA) synoviocytes differ from long-standing RA, suggesting that abnormal methylation occurs early in synovium and

APA, Harvard, Vancouver, ISO, and other styles

41

Polinski, K., E. Bemis, K. Demoruelle, et al. "SAT0596 ASSOCIATIONS BETWEEN CIRCULATING LIPID MEDIATORS AND INCIDENT INFLAMMATORY ARTHRITIS IN AN ANTI-CITRULLINATED PROTEIN ANTIBODY POSITIVE POPULATION." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1256.1–1256. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1884.

Full text

Abstract:

Background:Lipid mediators are endogenously derived from the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and have important roles in promoting and resolving inflammation in the body (1). Epidemiological studies have shown higher omega-3 PUFA status to be associated with a lower risk of both autoimmunity and progression to inflammatory arthritis (IA) (2,3).Objectives:To determine the association of lipid mediators with progression from rheumatoid arthritis (RA)-related autoimmunity to inflammatory arthritis (IA).Methods:We conducted a prospective cohort study using dat

APA, Harvard, Vancouver, ISO, and other styles

42

Jenkins, Rhys. "R. Evan Ellis, China on the Ground in Latin America: Challenges for the Chinese and Impacts on the Region (Basingstoke and New York: Palgrave Macmillan, 2014), pp. xiii + 320, £72.00, hb. - Kevin P. Gallagher, The China Triangle: Latin America's China Boom and the Fate of the Washington Consensus (Oxford and New York: Oxford University Press, 2016), pp. xvii + 232, £18.99; $27.95, hb. - Margaret Myers and Carol Wise (eds.), The Political Economy of China–Latin America Relations in the New Millennium: Brave New World (New York and London: Routledge, 2017), pp. vii + 293, £29.99, pb. - Yanran Xu, China's Strategic Partnerships in Latin America: Case Studies of China's Oil Diplomacy in Argentina, Brazil, Mexico, and Venezuela, 1991–2015 (Lanham, MD: Lexington Books, 2017), pp. ix + 157, £52.95, hb." Journal of Latin American Studies 51, no. 1 (2019): 187–91. http://dx.doi.org/10.1017/s0022216x19000014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Luo, Rui, Weelic Chong, Zhenchao Zhang, et al. "Abstract P5-06-05: Whole-genome bisulfite sequencing of single circulating tumor cells identifies cellular methylation heterogeneity in metastatic breast cancer." Cancer Research 83, no. 5_Supplement (2023): P5–06–05—P5–06–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-06-05.

Full text

Abstract:

Abstract Background: Although different patterns and changes in DNA methylation play an important role in cancer progression and tumor subtype differentiation, methylation remains relatively less understood in the context of tumor heterogeneity. Intra-tumor heterogeneity influences chemotherapy response, resistance development, and metastatic progression, and can be identified with liquid biopsy, a non-invasive approach to monitor cancer progression and provide predictive information. In this study, we sequenced circulating tumor cells (CTCs) to interrogate whole-genome methylation at single-c

APA, Harvard, Vancouver, ISO, and other styles

44

KITLV, Redactie. "Book Reviews." New West Indian Guide / Nieuwe West-Indische Gids 70, no. 1-2 (1996): 133–203. http://dx.doi.org/10.1163/13822373-90002634.

Full text

Abstract:

-Sandra L. Richards, Judy S.J. Stone, Theatre. London: Macmillan Caribbean, 1994. xii + 268 pp.-Lowell Fiet, Errol Hill, The Jamaican stage, 1655-1900: profile of a colonial theatre. Amherst: University of Massachusetts Press, 1992. xiv + 346 pp.-Supriya Nair, Bruce King, V.S. Naipaul. New York: St. Martin's Press, 1993. viii + 170 pp.-Agnes Lugo-Ortiz, Donald E. Rice, The rhetorical uses of the authorizing figure: Fidel Castro and José Martí. Westport CT: Praeger, 1992. xviii + 163 pp.-Graciella Cruz-Taura, Juan A. Martínez, Cuban art and national identity: The Vanguardia painters, 1927-1950.

APA, Harvard, Vancouver, ISO, and other styles

45

Hengel, Richard L., Sujatha Krishnan, Timothy E. Ritter, et al. "P-220. Real-World Effectiveness of Fecal Microbiota, live-jslm for the Prevention of Recurrent Clostridioides difficile Infection." Open Forum Infectious Diseases 12, Supplement_1 (2025). https://doi.org/10.1093/ofid/ofae631.424.

Full text

Abstract:

Abstract Background Fecal microbiota, live-jslm (RBL) is a live biotherapeutic product approved by the FDA in November 2022 for the prevention of recurrence of Clostridioides difficile infection (rCDI) in adults. It is a rectally administered, pre-packaged single dose microbiome therapy, demonstrated to be safe and efficacious in clinical trials. There are few real-world studies of RBL use in routine clinical practice. This study reports effectiveness of RBL in an outpatient real-world setting. Methods Medical records of patients who were administered RBL within physician offices nationally we

APA, Harvard, Vancouver, ISO, and other styles

46

fdsmnghj. "Dead by Daylight's K-Pop Chapter "All-Kill" Gets Official Release Date." March 28, 2021. https://doi.org/10.5281/zenodo.4642847.

Full text

Abstract:

Dead by Daylight's newest killer has been taking the internet by storm since he was announced earlier this month, with "The Trickster" bringing the world of K-pop to the popular online game. The unlikely crossover is currently only playable via the game's Public Test Build, but it seems that won't be the case for much longer, with Behaviour Interactive announcing today that the All-Kill DLC will launch next week. The announcement was made by the studio's official Twitter account, which showcased a short teaser alongside the release date. As expected for a Dead by Dayl

APA, Harvard, Vancouver, ISO, and other styles

47

Hengel, Richard L., Sujatha Krishnan, Jonathan A. Rosenberg, et al. "685. Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile." Open Forum Infectious Diseases 10, Supplement_2 (2023). http://dx.doi.org/10.1093/ofid/ofad500.747.

Full text

Abstract:

Abstract Background Fecal Microbiota, live-jslm (RBL) is a rectally administered, pre-packaged, live biotherapeutic approved in November 2022 for the prevention of recurrence of Clostridioides difficile infection (rCDI) in adults. As the first FDA-approved microbiota product, this new agent may pose challenges in administration, particularly with Infectious Disease (ID) or other specialties not typically providing rectally administered therapies. As part of an ongoing real-world study of RBL, the purpose of this study is to develop and report a simple protocol for the administration of RBL in

APA, Harvard, Vancouver, ISO, and other styles

48

"Recensions / Reviews." Canadian Journal of Political Science 34, no. 4 (2001): 845–924. http://dx.doi.org/10.1017/s0008423901778110.

Full text

Abstract:

Ajzenstat, Janet, Paul Romney, Ian Gentles and William D. Gairdner, eds. Canada's Founding Debates. By Alan Cairns 847Lazar, Harvey, ed. Canada: The State of the Federation 1999/2000: Toward a New Mission Statement for Canadian Fiscal Federalism. By Hugh Mellon 848Mouchon, Jean. La politique sous l'influence des médias; Monière, Denis. Démocratie médiatique et représentation politique: analyse comparative de quatre journaux télévisés : Radio-Canada, France 2, RTBF (Belgique) et TSR (Suisse); et Gingras, Anne-Marie. Médias et démocratie. Le grand malentendu. Par Maud Vuillardot 850Livingstone,

APA, Harvard, Vancouver, ISO, and other styles

49

Ramos, Gabriel Teixeira. "CARTOGRAFIAS E MOVIMENTOS." Revista Jatobá 1 (December 18, 2019). http://dx.doi.org/10.54686/revjat.v1i.61326.

Full text

Abstract:

Pelo menos desde 1960, cartografias produzidas pelo urbanismo no campo dos deslocamentos urbanos têm se limitado ao posicionamento geográfico do observador, desconsiderando, em boa medida, a experiência encarnada dos sujeitos para além do visual, bem como os atores e agentes político-estratégicos de formação do território. Em 1965, Kevin Lynch, Donald Appleyard e John Myer publicam “The view from the road” e estabelecem uma metodologia de análise da qualidade da forma visual da cidade contemporânea a partir de estradas. Inauguram, em certa medida, uma leitura através do para-brisa do automóvel

APA, Harvard, Vancouver, ISO, and other styles

50

Cashman, Dorothy Ann. "“This receipt is as safe as the Bank”: Reading Irish Culinary Manuscripts." M/C Journal 16, no. 3 (2013). http://dx.doi.org/10.5204/mcj.616.

Full text

Abstract:

Introduction Ireland did not have a tradition of printed cookbooks prior to the 20th century. As a consequence, Irish culinary manuscripts from before this period are an important primary source for historians. This paper makes the case that the manuscripts are a unique way of accessing voices that have quotidian concerns seldom heard above the dominant narratives of conquest, colonisation and famine (Higgins; Dawson). Three manuscripts are examined to see how they contribute to an understanding of Irish social and culinary history. The Irish banking crisis of 2008 is a reminder that comments

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!